Humana (NYSE:HUM) Receives Neutral Rating from Cantor Fitzgerald

Humana (NYSE:HUM)‘s stock had its “neutral” rating reaffirmed by investment analysts at Cantor Fitzgerald in a report issued on Wednesday,Benzinga reports. They currently have a $290.00 price target on the insurance provider’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 10.87% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on the company. Morgan Stanley lowered their price objective on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and lifted their target price for the stock from $247.00 to $308.00 in a research note on Wednesday, November 6th. Truist Financial upped their price target on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Piper Sandler lifted their price objective on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Finally, TD Cowen increased their target price on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Nineteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $291.32.

Humana Stock Up 1.6 %

Humana stock opened at $261.56 on Wednesday. The firm has a 50 day moving average price of $273.00 and a 200-day moving average price of $295.72. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a market capitalization of $31.49 billion, a P/E ratio of 23.07, a P/E/G ratio of 2.11 and a beta of 0.56.

Humana (NYSE:HUM) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, equities analysts predict that Humana will post 16.11 EPS for the current year.

Insider Buying and Selling at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.32% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Humana

A number of large investors have recently modified their holdings of the company. Creative Financial Designs Inc. ADV lifted its stake in shares of Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 61 shares during the last quarter. FPC Investment Advisory Inc. purchased a new position in shares of Humana in the fourth quarter worth $27,000. Centricity Wealth Management LLC bought a new stake in Humana during the 4th quarter valued at $30,000. Ashton Thomas Securities LLC purchased a new stake in Humana during the 3rd quarter valued at $31,000. Finally, Your Advocates Ltd. LLP boosted its position in Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.